Table 3 Comparisons between the anticoagulant and non-anticoagulant groups
Variables | Non-AC (%) | AC (%) | Before IPTW | After IPTW |
|---|---|---|---|---|
P value | P value | |||
Age (years) | Â | Â | 0.004 | 0.891 |
  < 74 | 78 (51.7) | 30 (37.5) |  |  |
 ≥ 74 | 73 (48.3) | 50 (62.5) |  |  |
Risk category | Â | Â | 0.106 | 0.947 |
 Very low–low | 9 (6.0) | 7 (8.8) |  |  |
 Intermediate | 26 (17.2) | 22 (27.5) |  |  |
 High–very high | 116 (76.8) | 51 (63.7) |  |  |
Gleason score | Â | Â | 0.211 | 0.987 |
 2–6 | 18 (11.9) | 15 (18.8) |  |  |
 7 | 67 (44.4) | 38 (47.5) |  |  |
 8–10 | 66 (43.7) | 27 (33.8) |  |  |
Initial PSA concentration (μg/L) |  |  | 0.138 | 0.802 |
  < 10 | 51 (33.8) | 37 (46.2) |  |  |
 10–20 | 50 (33.1) | 24 (30.0) |  |  |
  ≥ 20 | 50 (33.1) | 19 (23.8) |  |  |
T stage | Â | Â | 0.085 | 0.613 |
 T1–2 | 47 (31.1) | 34 (42.5) |  |  |
  ≥ T3 | 104 (68.9) | 46 (57.5) |  |  |
Diabetes | Â | Â | 0.001 | 0.883 |
 No | 130 (86.1) | 54 (67.5) |  |  |
 Yes | 21 (13.9) | 26 (32.5) |  |  |
Hypertension |  |  |  < 0.001 | 0.782 |
 No | 88 (58.3) | 26 (32.5) |  |  |
 Yes | 63 (41.7) | 54 (67.5) |  |  |
Cirrhosis | Â | Â | 0.560 | 0.698 |
 No | 145 (96.0) | 78 (97.5) |  |  |
 Yes | 6 (3.97) | 2 (2.50) |  |  |
Whole-pelvic radiotherapy | Â | Â | 0.202 | 0.575 |
 No | 101 (66.9) | 60 (75.0) |  |  |
 Yes | 50 (33.1) | 20 (25.0) |  |  |
Androgen-deprivation therapy | Â | Â | 0.231 | 0.973 |
 No | 31 (20.5) | 22 (27.5) |  |  |
 Yes | 120 (79.5) | 58 (72.5) |  |  |
Radiation dose | Â | Â | 0.462 | 0.788 |
 67.2 Gy | 53 (35.1) | 32 (40.0) |  |  |
 70 Gy | 98 (64.9) | 48 (60.0) |  |  |
IMRT technique | Â | Â | 0.360 | 0.893 |
 Static | 44 (29.1) | 28 (35.0) |  |  |
 Arc | 107 (70.9) | 52 (65.0) |  |  |